Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has successfully completed participation in one of the Phase 3 pivotal studies \[CB-03-01/25 and CB-03-01/26\].~* Participant agrees to use effective method of contraception throughout study, if applicable.~* Participant has provided written informed consent or assent.~* Participant is willing to comply with study instructions and return to the clinic for required visits.~Exclusion Criteria:~* Participant is pregnant, lactating, or is planning to become pregnant during the study.~* Participant has any skin disease or condition that could interfere with the safety evaluation of the test products or requires the use of interfering topical or systemic therapy.~* Participant has any condition which, in the investigator's opinion, would make it unsafe or unsuitable for the participant to participate in this research study.~* Participant plans to use any other investigational drug or device during participation in this study.~* Participant has known hypersensitivity or previous allergic reaction to the drug or any of its ingredients.~* Participant is or plans to use any restricted systemic and/or topical anti-acne preparations or medications during the study

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CB-03-01 cream, 1% (Type: EXPERIMENTAL): CB-03-01 (cortexolone 17α-propionate) Cream, 1%, applied twice daily to whole face (about 1 gram) and affected areas of trunk (if applicable) for up to an additional 9 months. Over the course of the study, treatment on the face and/or trunk may be discontinued if/when acne clears and re-started if/when acne worsens, according to the assessment of the investigator for each respective treatment area.

Based on this trial design, predict the completion outcome and termination type (if applicable).